

1 **Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype**
2 **SARS-CoV-2 specific T cells**

3
4 Catherine Riou^{1,2,*}, Georgia Schäfer^{1,3,4}, Elsa du Bruyn^{1,5}, Rene T. Goliath¹, Cari Stek^{1,5,6}, Huihui
5 Mou⁷, Deli Hung⁸, Katalin A. Wilkinson^{1,5,9}, Robert J. Wilkinson^{1,5,6,9}

6
7 ¹ Wellcome Centre for Infectious Disease Research in Africa and Institute of Infectious Disease
8 and Molecular Medicine, University of Cape Town, Observatory 7925, South Africa
9 ² Division of Immunology, Department of Pathology, University of Cape Town, Observatory
10 7925, South Africa
11 ³ International Centre for Genetic Engineering and Biotechnology (ICGEB) Cape Town,
12 Observatory 7925, South Africa
13 ⁴ Division of Medical Biochemistry and Structural Biology, Department of Integrative
14 Biomedical Sciences, University of Cape Town, Observatory 7925, South Africa
15 ⁵ Department of Medicine, University of Cape Town, Observatory 7925, South Africa
16 ⁶ Department of Infectious Diseases, Imperial College London, W12 0NN, UK
17 ⁷ Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL
18 33458, USA
19 ⁸ Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA
20 92037, USA
21 ⁹ The Francis Crick Institute, London, NW1 1AT, UK
22

23 * **Corresponding Author:** Catherine Riou, University of Cape Town, IDM, Anzio Road,
24 Observatory, 7925, Cape Town, South Africa. E-mail: cr.riou@uct.ac.za

25
26 **Key words:** COVID-19, T cells, Whole blood Assay

27
28 **Running title:** SARS-CoV-2-specific whole blood T cell assay.

29
30 **40-word summary:** In this proof of concept study, we show that SARS-CoV-2 T cell responses
31 are easily detectable using a rapid whole blood assay requiring minimal blood volume. Such
32 assay could represent a suitable tool to monitor adaptive immunity in vaccine trials.

33 **ABSTRACT**

34

35 Rapid tests to evaluate SARS-CoV-2-specific T cell responses are urgently needed to decipher
36 protective immunity and aid monitoring vaccine-induced immunity. Using a rapid whole blood
37 assay requiring minimal amount of blood, we measured qualitatively and quantitatively SARS-
38 CoV-2-specific CD4 T cell responses in 31 healthcare workers, using flow cytometry. 100% of
39 COVID-19 convalescent participants displayed a detectable SARS-CoV-2-specific CD4 T cell
40 response. SARS-CoV-2-responding cells were also detected in 40.9% of participants with no
41 COVID-19-associated symptoms or who tested PCR negative. Phenotypic assessment indicated
42 that, in COVID-19 convalescent participants, SARS-CoV-2 CD4 responses displayed an early
43 differentiated memory phenotype with limited capacity to produce IFN γ . Conversely, in
44 participants with no reported symptoms, SARS-CoV-2 CD4 responses were enriched in late
45 differentiated cells, co-expressing IFN γ and TNF α and also Granzyme B. This proof of concept
46 study presents a scalable alternative to PBMC-based assays to enumerate and phenotype SARS-
47 CoV-2-responding T cells, thus representing a practical tool to monitor adaptive immunity in
48 vaccine trials.

49 INTRODUCTION

50

51 The outbreak of SARS-CoV-2 infection (causing the disease known as COVID-19) that first
52 emerged in Wuhan, China in December 2019, was declared a global pandemic on 12th March
53 2020, and is affecting all countries of the world, including those of Africa (Margolin et al., 2020).

54 There is an urgent need to understand better the clinical manifestations and the pathogenesis of
55 SARS-CoV-2 in order to develop relevant tools, including diagnostic tests, treatments and
56 vaccines, to stop the spread of disease as well as strategies to best manage this disease in all
57 population groups.

58

59 The clinical spectrum of COVID-19 is very wide, from asymptomatic through mild flu-like
60 symptoms to severe pneumonia and death. Understanding what constitutes immune protection
61 against SARS-CoV-2 is key to predicting long-term immunity and to inform vaccine design.

62 While much emphasis has been placed on the B cell and antibody response, it is not yet clear
63 what type of immune response confers protection to SARS-CoV-2 (Cox and Brokstad, 2020).

64 Several studies suggest that the T cell response may play an important role in SARS-CoV-2
65 pathogenesis and reports indicating that patients lacking B cells can recover from SARS-CoV-2
66 infection further highlight the likely importance of T cell immunity (Altmann and Boyton, 2020);
67 (Quinti et al., 2020). Additionally, accumulating evidence indicates that the presence of pre-
68 existing, cross-reactive memory T cells specific for common cold coronaviruses may affect
69 susceptibility to SARS-CoV-2 infection and partially explain the markedly divergent clinical
70 manifestations of COVID-19 (Braun et al., 2020; Canete and Vinuesa, 2020; Lipsitch et al., 2020;
71 Sette and Crotty, 2020).

72

73 Efficient, sensitive and simple assessment of human T-cell immunity remains a challenge. Most
74 commonly used T cell assays necessitate the isolation of peripheral blood mononuclear cells

75 (PBMC), requiring significant amount of blood. Therefore, whole blood assays could be more
76 advantageous than PBMC-based methods, by significantly reducing blood volume (~ 1 ml),
77 making them more applicable to paediatric populations. Moreover, such assays are rapid, as they
78 don't require cell separation, and preserve the physiologic cellular and soluble environments,
79 mimicking better human blood condition. Here we report a rapid (~ 7 hrs) whole blood-based
80 detection method of SARS-CoV-2-specific T cell responses with simple steps that could be
81 adapted to settings of limited resources. This rapidly applicable assay could represent an easily
82 standardizable tool to assess SARS-CoV-2-specific adaptive immunity to monitor T cell
83 responses in vaccine trials, gain insight into what constitutes a protective response, or define the
84 prevalence of SARS-CoV-2 T cell responders population wide.

85 **METHODS**

86

87 ***Study population***

88 The population studied consisted of healthcare workers (HCW, n=31, 29% male) recruited
89 between July and September 2020, from Groot Schuur Hospital in Cape Town, the hardest hit
90 region of the initial COVID-19 epidemic in South Africa (Mendelson et al., 2020). Participants
91 were classified according to i) reporting of COVID-19-associated symptoms, ii) whether a
92 SARS-CoV-2 RNA PCR from a nasal or pharyngeal swab was performed and iii) SARS-CoV-2
93 PCR results. Based on these criteria, participants were subdivided into three groups: 1) persons
94 with no COVID-19-associated symptoms (n=15); 2) persons who reported symptoms but tested
95 SARS-CoV-2 PCR negative (n = 7); and 3) persons who had COVID-19-associated symptoms
96 and tested SARS-CoV-2 PCR positive (n = 9) (**Table 1**). In all groups, the exposure to COVID-
97 19 patients was comparable (86.8 to 100%). All participants with PCR confirmed COVID-19 had
98 mild symptoms and did not require hospitalization. Blood samples were obtained a median of 7.3
99 weeks post-SARS-CoV-2 testing in persons with a negative test results and 4.7 weeks in those
100 with a confirmed positive result (p=0.09). All participants were symptom-free at the time of
101 sampling. In four SARS-CoV-2 PCR positive participants, a second sample was obtained 1
102 month later. The University of Cape Town's Faculty of Health Sciences Human Research Ethics
103 Committee approved the study (HREC: 207/2020) and written informed consent was obtained
104 from all participants.

105

106 ***Measurement of SARS-CoV-2 nucleocapsid-specific IgG in plasma***

107 The measurement of SARS-CoV-2 specific antibodies was performed using the Roche Elecsys®
108 Anti-SARS-CoV-2 immunoassay (Roche Diagnostics, Basel, Switzerland). This semi-
109 quantitative electro-chemiluminescent immunoassay measures SARS-CoV-2 nucleocapsid-
110 specific IgG. The assay was performed by the South African National Health Laboratory Service

111 (NHLS) and interpreted according to manufacturers' instructions (Roche: V 1.0 2020-05).
112 Results are reported as numeric values in form of a cut-off index (COI; signal sample/cut-off),
113 where a COI < 1.0 corresponds to non-reactive plasma and COI \geq 1.0 to reactive plasma. At 14
114 days post-SARS-CoV-2 PCR confirmation, the sensitivity and specificity of the Elecsys® Anti-
115 SARS-CoV-2 immunoassay is reported as 99.5% (95% CI, 97.0 to 100.0%) and 99.80% (95%
116 CI, 99.69 to 99.88%), respectively (Favresse et al., 2020; Muench et al., 2020; National, 2020).

117

118 **SARS-CoV-2 pseudovirus neutralisation assay**

119 Patient plasma was evaluated for SARS-CoV-2 neutralisation activity using a SARS-CoV-2
120 pseudovirus infection assay. Single-cycle infectious SARS-CoV-2 pseudovirions based on the
121 HIV backbone expressing the SARS-CoV-2 Spike (S) protein and a firefly luciferase reporter
122 were produced in HEK-293TT cells (Buck et al., 2004; Buck et al., 2005) by co-transfection of
123 plasmids pNL4-3.Luc.R-.E- (NIH AIDS Reagent Program (#3418), Germantown, MD, USA) and
124 pcDNA3.3-SARS-CoV-2-spike Δ 18 (Rogers et al., 2020). HEK-293TT cell culture supernatants
125 containing the virions were harvested 3 days post transfection and incubated with heat-inactivated
126 patient plasma at 5-fold serial dilutions for 60 min at 37°C. Plasma/pseudovirus mixtures were
127 then used for transfection of HEK-293T cells stably expressing the ACE2 receptor (Mou et al.,
128 2020). Cells were lysed 3 days post infection using the Promega cell culture lysis reagent
129 (Promega Biosciences Inc., San Luis Obispo, CA, USA) and assessed for luciferase activity using
130 a GloMax® Explorer Multimode Microplate Reader (Promega Biosciences) together with the
131 Luciferase assay system (Promega Biosciences).

132

133 ***Whole blood-based T cell detection assay***

134 Blood was collected in sodium heparin tubes and processed within 3 h of collection. The whole
135 blood-based SARS-CoV-2-specific T cell detection assay was adapted from a previously reported
136 whole blood intracellular cytokine detection assay designed to quantitate *Mycobacterium*

137 *tuberculosis* specific T cells in small volumes of blood (Hanekom et al., 2004). However,
138 significant modifications have been made, including a reduced incubation time, the usage of a
139 fixation buffer allowing the simultaneous lysis of red blood cells to streamline processing time,
140 leading to faster acquisition of results (Riou et al., 2020). Here, we adapted this assay to detect
141 SARS-CoV-2 specific T cells using synthetic SARS-CoV-2 PepTivator peptides (Miltenyi
142 Biotec, Surrey, UK), consisting of 15-mer sequences with 11 amino acid overlap covering the
143 immunodominant parts of the spike (S) protein, and the complete sequence of the nucleocapsid
144 (N) and membrane (M) proteins. All peptides were combined in a single pool and used at a final
145 concentration of 1 µg/ml. The workflow of the assay is presented in **Figure 1**. Briefly, 400 µl
146 whole blood was stimulated with the SARS-CoV-2 S, N and M protein peptide pool at 37°C for 5
147 hrs in the presence of the co-stimulatory antibodies against CD28 and CD49d (1 µg/ml each; BD
148 Biosciences, San Jose, CA, USA) and Brefeldin-A (10 µg/ml, Sigma-Aldrich, St Louis, MO,
149 USA). Unstimulated blood was incubated with co-stimulatory antibodies, Brefeldin-A and an
150 equimolar amount of DMSO. Red blood cell lysis and white cell fixation was then performed as a
151 single step using a Transcription Factor Fixation buffer (eBioscience, San Diego, CA, USA) for
152 20 minutes. At this stage cells were cryopreserved in freezing media (50% foetal bovine serum,
153 40% RPMI and 10% dimethyl sulfoxide) and stored in liquid nitrogen until batched analysis.
154
155 Cell staining was performed on cryopreserved cells that were thawed, washed and permeabilised
156 with a Transcription Factor perm/wash buffer (eBioscience). Cells were then stained at room
157 temperature for 30 min with antibodies for CD3 BV650, CD4 BV785, CD8 BV510, CD45RA
158 Alexa 488, CD27 PE-Cy5, CD38 APC, HLA-DR BV605, Ki67 PerCP-cy5.5, PD-1 PE,
159 Granzyme B (GrB) BV421, IFN γ BV711, TNF α PE-Cy7 and IL-2 PE/Dazzle 594, as detailed in
160 **Supplementary Table 1**. Samples were acquired on a BD LSR-II and analysed using FlowJo
161 (v9.9.6, FlowJo LCC, Ashland, OR, USA). A positive response was defined as any cytokine
162 response that was at least twice the background of unstimulated cells. To define the phenotype of

163 SARS-CoV-2-specific CD4 T cells, a cut-off of 30 events was used. The gating strategy is
164 provided in **Supplementary Figure 1**.

165

166 *Statistical analyses*

167 Graphical representations were performed in Prism (v8.4.3; GraphPad Software Inc, San Diego,
168 CA, USA) and JMP (v14.0.0; SAS Institute, Cary, NC, USA). Statistical tests were performed in
169 Prism. Non-parametric tests were used for all comparisons. The Kruskal-Wallis test with Dunn's
170 multiple comparison test was used for multiple comparisons and the Mann-Whitney and
171 Wilcoxon matched pairs test for unmatched and paired samples, respectively.

172 **RESULTS**

173

174 ***Serological assessment of SARS-CoV-2 sensitization.***

175 Even though RT-PCR is the most specific technique to detect acute SARS-CoV-2 infection, the
176 positivity rate drops rapidly as soon as 10 days post-symptom onset, particularly in individuals
177 with mild forms of COVID-19 (Liu et al., 2020a; Liu et al., 2020b). Hence, serology assays
178 provide an important complement to RNA testing to identify individuals who have been
179 sensitized by SARS-CoV-2. Thus, to assess potential SARS-CoV-2 sensitization in participants
180 who did not have a SARS-CoV-2 PCR test performed or tested PCR negative, the presence of
181 SARS-CoV-2-specific antibodies (e.g. SARS-CoV-2 nucleocapsid-specific IgG) was measured
182 and a SARS-CoV-2 pseudovirus neutralisation assay was also performed in all participants.

183 While all participants with a positive SARS-CoV-2 PCR test exhibited *in vitro* anti-SARS-CoV-2
184 neutralizing activity and 8/9 (88.8%) had detectable SARS-CoV-2 nucleocapsid-specific IgG,
185 none of the participants who tested negative or did not undergo PCR testing were positive for
186 SARS-CoV-2 nucleocapsid-specific IgG (**Figure 2A**) or displayed robust *in vitro* anti-SARS-
187 CoV-2 activity (**Figure 2B**). Overall, these results confirmed that PCR positive participants had
188 been infected with SARS-CoV-2 and mounted an immune response to the virus and suggested
189 that none of the participants who did not have a PCR test performed or tested PCR negative,
190 despite experiencing COVID-19-like symptoms, have been SARS-CoV-2 infected.

191

192 ***Magnitude and functional profile of SARS-CoV-2-responding CD4 T cells.***

193 Amongst the 31 participants tested, 58% (n=18) had a detectable SARS-CoV-2-specific CD4 T
194 cell response (producing any of the measured cytokines, IFN γ , TNF α or IL-2) using the described
195 whole blood assay (**Figure 3A**). We then defined the magnitude and phenotype of SARS-CoV-2
196 -specific CD4 responses according to participants' clinical characteristics (**Figure 3B&C**). All
197 HCW with self-reported symptoms and a SARS-CoV-2 PCR positive test (n=9) were found to

198 have SARS-CoV-2-specific CD4 T cells (median frequency: 0.47%, IQR: 0.28-0.65) (**Figure**
199 **3C**). Of note, the frequency of SARS-CoV-2 specific CD4 T cells did not associate with the
200 magnitude of SARS-CoV-2 nucleocapsid-specific IgG ($p = 0.64$, $r = -0.18$) or plasma
201 neutralizing activity ($p = 0.46$, $r = 0.28$) (data not shown). Interestingly, in participants with no
202 detectable SARS-CoV-2 nucleocapsid-specific IgG or neutralizing antibody activity, of those
203 with self-reported symptoms, 3/7 (43%) had detectable SARS-CoV-2-responding CD4 T cells
204 (median of responders: 0.02%, IQR: 0.019-0.03) and 6/15 (40%) of those with no self-reported
205 symptoms had detectable SARS-CoV-2-responding CD4 T cells (median of responders: 0.15%,
206 IQR: 0.05-1.47), suggesting that these responses correspond to SARS-CoV-2 cross-reactive
207 memory CD4 T cells.

208 Next, we defined the polyfunctional profile of SARS-CoV-2-responding CD4 T cells, based on
209 their capacity to co-express IL-2, IFN γ or TNF α (**Figure 3D**). The overall functional profile of
210 SARS-CoV-2-specific cells in PCR positive participants was distinct from participants with no
211 reported symptoms ($p=0.0002$). Indeed, the SARS-CoV-2-specific CD4 response in PCR+
212 participants was characterized by limited expression of IFN γ and was enriched in cells co-
213 expressing IL-2 and TNF α . On the contrary, in participants reporting no symptom, most SARS-
214 responding CD4 cells were distributed between triple functional cells (IL-2+IFN γ +TNF α +) and
215 cells co-producing IFN γ and TNF α . Overall, in this assay TNF α was the predominant cytokine
216 produced, with its production being significantly higher compared to IL-2 ($p = 0.0026$) and IFN γ
217 ($p < 0.0001$) (**Supplementary Figure 2**).

218

219 *Phenotypic assessment of SARS-CoV-2-responding CD4 T cells*

220 While the proposed assay can be performed using a limited antibody panel to identify the
221 frequency of SARS-CoV-2-responding T cells, by solely measuring cytokine production, the use
222 of a more extensive antibody panel also permits definition of the phenotypic profile of these cells.
223 To this end, we included additional markers to assess the memory differentiation (CD27,

224 CD45RA), cytotoxic potential (GrB) and activation profile (HLA-DR, CD38, Ki67, PD-1) of
225 SARS-CoV-2-responding CD4 T cells.

226 **Figure 4A&B** shows that in all individuals with symptoms, SARS-CoV-2-specific CD4 T cells
227 displayed almost exclusively (median: 97.7%) an early differentiated memory phenotype (ED:
228 CD45RA-CD27+). On the contrary, in 4/6 HCW with no symptoms, SARS-CoV-2-specific CD4
229 T cells exhibited a predominant late differentiated phenotype (LD: CD45RA-CD27-).

230 While the role of cytotoxic CD4 T cells is still unclear, the presence of these cells has been
231 described in several viral infections (Juno et al., 2017). We thus measured GrB expression in
232 SARS-CoV-2-responding CD4 T cells. While GrB was barely detectable in SARS-CoV-2-
233 specific CD4 T cells in PCR positive participants, elevated GrB expression was observed in 4 out
234 of 6 participants without symptoms (**Figure 4C&D**). Moreover, the proportion of ED SARS-
235 CoV-2-responding CD4 T cells inversely associated with GrB expression ($p = 0.002$, $r = -0.71$)
236 and the proportion of IFN γ and TNF α dual producing cells ($p < 0.0001$, $r = -0.84$) (**Figure 4E**).
237 The phenotypic characteristics of GrB expressing SARS-CoV-2-responding CD4 T cells (i.e.
238 highly differentiated and producing IFN γ and TNF α) are in agreement with a recent report
239 describing CMV-specific CD4 CTL T cells (Pachnio et al., 2016).

240
241 To determine if the overall phenotypic profile of SARS-CoV-2-responding CD4 T cells allowed
242 discrimination of participants based on their clinical characteristics, we performed a hierarchical
243 clustering analysis (**Figure 5A**) and a principal component analysis (PCA) (**Figure 5B**),
244 including four parameters (e.g. proportion of IFN γ +TNF α +IL2+ and IFN γ -TNF α +IL2+ cells,
245 proportion of ED, and GrB expression). Both analyses show that participants who reported no
246 symptoms and were negative for SARS-CoV-2 Abs separated clearly from PCR positive
247 participants. Conversely, PCR and SARS-CoV-2 antibody negative HCWs reporting symptoms
248 could not be separated from PCR positive participants. The loading plot shows that GrB
249 expression and the proportion of triple positive cells were the main drivers permitting the

250 segregation of participants who reported no symptoms and were negative for SARS-CoV-2 Abs
251 (**Figure 5C**)

252

253 Lastly, as the expression of activation markers (HLA-DR, CD38, PD-1 or Ki67) on antigen-
254 specific T cells are indicative of active infection (Chen and Wherry, 2020; Mathew et al., 2020),
255 we defined the expression of these markers on SARS-CoV-2-responding CD4 T cells. No
256 significant difference was observed in any of the measured markers amongst the different groups,
257 notwithstanding a few outliers observed in the PCR positive participant group (**Figure 6A**).

258 Interestingly, regardless of the participants' clinical characteristics, PD-1 expression was highly
259 expressed on SARS-CoV-2-responding CD4 T cells, raising the question of a potential intrinsic
260 dysfunction/exhaustion of coronavirus-specific memory CD4 T cells (Jubel et al., 2020; Wherry
261 and Kurachi, 2015; Wykes and Lewin, 2018). We then defined the relationship between the
262 activation profile of SARS-CoV-2-specific CD4 T cells and time post positive PCR test.

263 **Figure 6B** shows that in PCR positive participants, the expression of CD38 associated strongly
264 with the time post PCR testing ($p < 0.0001$, $r = -0.91$), where CD38 expression decreased sharply
265 in the first 2 to 3 weeks post testing, suggesting a rapid clearance of the pathogen. Similar
266 associations were observed for all tested activation markers, with CD38 expression showing the
267 strongest correlation (**Figure 6C**).

268 **DISCUSSION**

269

270 In this proof of concept analysis assessing the use of a simple whole blood assay to
271 measure SARS-CoV-2-specific T cell responses in a small health care worker cohort, we show
272 that SARS-CoV-2-specific CD4 T cells (expressing IFN γ , TNF α or IL-2) were easily detectable
273 in all tested convalescent COVID-19 participants. However, in participants who did not
274 experience any COVID-19-related symptoms or tested SARS-CoV-2 PCR negative (despite
275 reporting symptoms), 9/22 (40.9%) also exhibited a detectable SARS-CoV-2-specific CD4 T cell
276 response. Nevertheless, the median frequency of SARS-CoV-2-specific CD4 T cells in the latter
277 groups was \sim 5-fold lower compared to SARS-CoV-2 PCR positive participants. Importantly,
278 unlike convalescent COVID-19 participants, none of participants without symptoms or who
279 tested PCR negative had detectable SARS-CoV-2 nucleocapsid-specific IgG or displayed robust
280 neutralizing activity. This strongly suggests that in these participants, SARS-CoV-2-responding
281 CD4 T cells may correspond to a pre-existing cross-reactive memory CD4 T cell response. Thus,
282 the sole presence SARS-CoV-2-reactive CD4 T cells does not permit to infer SARS-CoV-2
283 infection or sensitization. These findings are in line with a number of studies demonstrating the
284 presence of SARS-CoV-2-reactive CD4 T cells in 40 to 60% of SARS-CoV-2-unexposed
285 individuals in different populations around the world (Grifoni et al., 2020; Le Bert et al., 2020;
286 Rydyznski Moderbacher et al., 2020; Sekine et al., 2020). Additionally, it is important to point
287 out that all these studies were performed using PBMC and it is encouraging to find that a whole
288 blood-based assay using limited amount of blood ($<$ 1ml) yields comparable results.

289 Further analyses of the polyfunctional and phenotypical profile of SARS-CoV-2-specific
290 CD4 T cells revealed that regardless of the clinical characteristics of the participants, the most
291 prevalent cytokine detected in response to SARS-CoV-2 peptides was TNF α . These observations
292 are in accordance with other studies pointing out an impairment of SARS-CoV-2 adaptive
293 immune responses, characterized by low level of type I and type II interferon (Blanco-Melo et al.,

294 2020; Sattler et al., 2020). However, it is also possible that the limited IFN γ production, we
295 observed in this study, is related to the short stimulation time (e.g. 5hrs) used in the assay.
296 Nevertheless, this suggests that TNF α could be a more reliable target than IFN γ , to detect SARS-
297 CoV-2-specific CD4 T cell responses. Additionally, SARS-CoV-2-responding CD4 T cells in all
298 participants were characterized by elevated of PD-1 expression. Such profiles have been observed
299 in acute SARS-CoV-2 infection and is likely driven by ongoing viral replication (Schub et al.,
300 2020; Sekine et al., 2020; Zheng et al., 2020). However, PD-1 expression on antigen-specific T
301 cells has been shown to decrease upon pathogen clearance (Barber et al., 2006; Sester et al.,
302 2008). Thus, elevated PD-1 expression in COVID-19 convalescent persons and uninfected
303 responders could reflect an intrinsic state of functional exhaustion of SARS-CoV-2-reactive
304 memory CD4 T cells.

305 Lastly, SARS-CoV-2-responding CD4 T cells were qualitatively different between
306 convalescent COVID-19 participants and participants who did not experience COVID-19-
307 associated symptoms. In the former group, SARS-CoV-2-specific CD4 T cells displayed almost
308 exclusively an early differentiated memory phenotype; while in the latter group, SARS-CoV-2-
309 responsive CD4 T cells exhibited a late differentiated memory phenotype and were enriched in
310 GrB. Differences in the attributes of SARS-CoV-2-reactive T cells distinguishing recent SARS-
311 CoV-2 infection from pre-existing immunity have been recently reported: strong *ex vivo* Elispot
312 responses and enhanced proliferation capacity were frequently observed in confirmed COVID-19
313 patients but rare in pre-pandemic or unexposed seronegative persons (Ogbe et al., 2020). This is
314 consistent with the phenotypic features we observed in our study. It remains to be determined
315 whether the presence of pre-existing cross-reactive memory T cells offers any protection against
316 SARS-CoV-2.

317 Although our results rely on a small number of participants and need to be confirmed in
318 larger cohorts, this study suggests that a whole blood assay could represent a valuable tool to
319 assess SARS-CoV-2-specific adaptive immunity. The whole blood assay described here is rapid

320 and scalable for varying complexities depending on laboratory resources and questions to be
321 addressed. It can be adapted to a simple 4-colour flow cytometry assay to monitor the frequency
322 of T cell responses in epidemiological studies or vaccine trials. Alternatively, it can also be used
323 to characterize in more depth the specific attributes of SARS-CoV-2-specific T cells, as shown
324 here, to aid deciphering cellular features that may associate with immune correlates of protection.
325 Finally, as this standardizable assay requires a limited volume of blood, it can be easily used in
326 COVID-19 paediatric cases.

327 **Acknowledgment:** The authors thank all the participants.

328

329 **Funding sources:** This work was supported by Wellcome [grant number: 104803 and 203135]
330 and Crick idea to innovation (i2i) scheme in partnership with the Rosetrees Trust [grant number:
331 2020-0009]. CR is supported by the European and Developing Countries Clinical Trials
332 Partnership EDCTP2 programme supported by the European Union (EU)'s Horizon 2020
333 programme [grant number: Training and Mobility Action TMA2017SF-1951-TB-SPEC to CR]
334 and the National Institutes of Health (NIH) [grant number:R21AI148027 to CR]. GS is supported
335 by the European and Developing Countries Clinical Trials Partnership EDCTP2 programme
336 [grant number: Training and Mobility Action TMA2018SF-2446 to GS]. RJW and KAW receive
337 support from the Francis Crick institute, which is funded by the UK Medical Research Council
338 UKRI, Cancer Research UK and Wellcome [grant number: FC0010218].

339

340 **Author contributions:** CR, KAW and RJW designed the study. CR performed the whole blood
341 assay and flow cytometry experiments and analysed and interpreted the data. GS performed the
342 neutralizing assay experiments. EdB, RTG and CS recruited the study participants. KAW, HM
343 and EL provided critical reagents. CR and KAW wrote the manuscript with all authors
344 contributing to providing critical feedback.

345

346 **Conflict of interest:** The authors declare no conflict of interest.

347 **FIGURE LEGENDS**

348

349 **Figure 1: Schematic showing methodology and workflow of the whole blood assay for the**
350 **detection of SARS-CoV-2-specific adaptive immune responses. Step 1:** 400 µl of heparinized
351 whole blood is incubated for 5 hours in the presence of a SARS-CoV-2-specific peptide pool in
352 the presence of co-stimulatory antibodies (i.e. CD28 and CD49d) and Brefeldin-A. **Step 2:** Cells
353 are incubated for 20 min in the presence of a transcription factor fixation buffer, leading to the
354 simultaneous lysis of red blood cells and cell fixation. **Step 3:** Cells are stained for 30 min with
355 an optimized panel of fluorophore labelled antibodies. **Step 4:** Samples are acquired on a flow
356 cytometer. Control samples are processed with a similar workflow in the absence of SARS-CoV-
357 2-specific peptide pool.

358

359 **Figure 2: SARS-CoV-2 serological assessment. A-** Quantification of SARS-CoV-2
360 Nucleocapsid-specific antibodies using the Elecsys[®] Roche assay expressed as a cut-off index
361 (signal sample/cut-off). Participants were grouped according to their clinical characteristics
362 (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-
363 CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Bars
364 represent the medians. The dotted line indicates the manufacturer's cut-off value for positivity.
365 Statistical comparisons were performed using a Mann-Whitney T- test. **B-** SARS-CoV-2
366 pseudovirus neutralization activity. SARS-CoV-2 pseudovirions pre-incubated with serially
367 diluted patient plasma were used to infect ACE2-expressing HEK-293T cells. Luciferase activity
368 as a measure for infection was assessed 3 days post-infection, and results are expressed as
369 infection compared to control (untreated virions, grey shaded area) which was set 100%.

370

371 **Figure 3: Magnitude and functional profile of SARS-CoV-2-specific CD4 T cells. A-**
372 Proportion of participants exhibiting a detectable SARS-CoV-2-specific CD4 T cell response. **B-**

373 Representative examples of TNF α and IFN γ production in CD4 T cells in response to SARS-
374 CoV-2 peptide pool. NS: no stimulation. C- Magnitude of SARS-CoV-2-specific CD4 T cell
375 response (expressed as a percentage of total CD4 T cells) in participants grouped according to
376 their clinical characteristics (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-
377 reported symptoms, SARS-CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-
378 2 PCR positive). The number of participants and % of responders in each group is presented at
379 the bottom of the graph. Statistical comparisons were performed using the Kruskal-Wallis test. D-
380 Polyfunctional profile of SARS-CoV-2-specific CD4 T cells in each group. The x-axis displays
381 the composition of each combination which is denoted with a dot for the presence of IL-2, IFN γ
382 and TNF α . The medians (black bar) are shown. Each combination is color-coded, and data are
383 summarized in the pie charts, where each pie slice represents the median contribution of each
384 combination to the total SARS-CoV-2 response. The arcs identify the contribution of TNF α (light
385 grey), IL-2 (grey) and IFN γ (black) to SARS-CoV-2 response. The Wilcoxon Rank Sum Test was
386 used to compare response patterns between groups. Statistical differences between pie charts
387 were defined using a permutation test.

388

389 **Figure 4: Memory differentiation profile and Granzyme B (GrB) expression in SARS-CoV-**

390 **2-specific CD4 T cells. A-** Representative examples of the memory differentiation profile of

391 SARS-CoV-2-specific CD4 T cells based on the expression of CD45RA and CD27. The flow

392 plot on the right shows the distribution of Naïve (CD45RA+CD27+), Early differentiated (ED:

393 CD45RA-CD27+), Late differentiated (LD: CD45RA-CD27-) and Effector (Eff:

394 CD45RA+CD27-) in total CD4 T cells. **B-** Summary graph of the proportion of ED and LD in

395 SARS-CoV-2-specific CD4 T cells in each group (Blue: no symptoms, no SARS-CoV-2 PCR

396 performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported

397 symptoms, SARS-CoV-2 PCR positive). Statistical comparisons were performed using the

398 Kruskal-Wallis test. **C-** Representative examples of GrB expression in total and SARS-CoV-2-

399 specific CD4 T cells. **D-** Summary graph of GrB expression in SARS-CoV-2-specific CD4 T
400 cells in each group. Statistical comparisons were performed using the Kruskal-Wallis test. **E-**
401 Relationship between the proportion of ED within SARS-CoV-2-specific CD4 T cells and GrB
402 expression or the proportion of IFN γ +TNF α +IL2- SARS-CoV-2-specific CD4 T cells.
403 Correlations were tested by a two-tailed non-parametric Spearman rank test.

404

405 **Figure 5: Phenotypic signature of SARS-CoV-2-specific IFN γ + CD4+ T cells according to**
406 **clinical characteristics. A-** Non-supervised two-way hierarchical cluster analysis (HCA, Ward
407 method) using three phenotypic parameters (i.e. GrB expression and the proportion of ED and
408 IFN γ +TNF α +IL2-) from SARS-CoV-2-specific CD4 T cells. Each column represents a
409 participant and is color-coded according to their clinical characteristics indicated by a dot at the
410 top of the dendrogram (Blue: no symptoms, no SARS-CoV-2 PCR performed; Orange: self-
411 reported symptoms, SARS-CoV-2 PCR negative; and Red: self-reported symptoms, SARS-CoV-
412 2 PCR positive). Participants with a positive SARS-CoV-2 serology test are indicated by a black
413 box and a white box identifies SARS-CoV-2 antibody-negative subjects. Data are depicted as a
414 heatmap coloured from minimum to maximum values for each parameter. **B-** Principal
415 component analysis on correlations, derived from the three studied parameters. Each dot
416 represents a participant. The two axes represent principal components 1 (PC1) and 2 (PC2). Their
417 contribution to the total data variance is shown as a percentage. **C-** Loading plot showing how
418 each parameter influences PC1 and PC2 values.

419

420 **Figure 6: Activation profile of SARS-CoV-2-specific CD4 T cells. A-** CD38, HLA-DR, Ki67
421 and PD-1 expression in SARS-CoV-2-specific CD4 T cells in each group (Blue: no symptoms,
422 no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative
423 and Red: self-reported symptoms, SARS-CoV-2 PCR positive). No significant differences were
424 observed between groups for any markers, using the Kruskal-Wallis test. **B-** Association between

425 CD38 expression in SARS-CoV-2-specific CD4 T cells and the time post SARS-CoV-2 PCR
426 positive test (weeks). Each symbol represents a participant (n=9). Dotted red lines identify
427 participant with longitudinal samples. Correlations were tested by a two-tailed non-parametric
428 Spearman rank test. C- Comparison of the correlation between the time post SARS-CoV-2 PCR
429 positive test (weeks) and the expression of different activation profile markers, ranked according
430 to the strength of the association. Spearman correlation r values are plotted on the x-axis and
431 corresponding P -values are shown within each bar.

432 REFERENCES

433

- 434 Altmann, D.M., and R.J. Boyton. 2020. SARS-CoV-2 T cell immunity: Specificity, function,
435 durability, and role in protection. *Sci Immunol* 5. DOI: 10.1126/sciimmunol.abd6160:
- 436 Barber, D.L., E.J. Wherry, D. Masopust, B. Zhu, J.P. Allison, A.H. Sharpe, G.J. Freeman, and R.
437 Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection.
438 *Nature* 439:682-687.
- 439 Blanco-Melo, D., B.E. Nilsson-Payant, W.C. Liu, S. Uhl, D. Hoagland, R. Moller, T.X. Jordan,
440 K. Oishi, M. Panis, D. Sachs, T.T. Wang, R.E. Schwartz, J.K. Lim, R.A. Albrecht, and
441 B.R. tenOever. 2020. Imbalanced host response to SARS-CoV-2 drives development of
442 COVID-19. *Cell* 181:1036-1045 e1039.
- 443 Braun, J., L. Loyal, M. Frentsch, D. Wendisch, P. Georg, F. Kurth, S. Hippenstiel, M. Dingeldey,
444 B. Kruse, F. Fauchere, E. Baysal, M. Mangold, L. Henze, R. Lauster, M.A. Mall, K.
445 Beyer, J. Rohmel, S. Voigt, J. Schmitz, S. Miltenyi, I. Demuth, M.A. Muller, A. Hocke,
446 M. Witzernath, N. Suttorp, F. Kern, U. Reimer, H. Wenschuh, C. Drosten, V.M. Corman,
447 C. Giesecke-Thiel, L.E. Sander, and A. Thiel. 2020. SARS-CoV-2-reactive T cells in
448 healthy donors and patients with COVID-19. *Nature* Doi: 10.1038/s41586-020-2598-9:
- 449 Buck, C.B., D.V. Pastrana, D.R. Lowy, and J.T. Schiller. 2004. Efficient intracellular assembly of
450 papillomaviral vectors. *J Virol* 78:751-757.
- 451 Buck, C.B., D.V. Pastrana, D.R. Lowy, and J.T. Schiller. 2005. Generation of HPV pseudovirions
452 using transfection and their use in neutralization assays. *Methods Mol Med* 119:445-462.
- 453 Canete, P.F., and C.G. Vinuesa. 2020. COVID-19 makes B cells forget, but T cells remember.
454 *Cell* 183:13-15.
- 455 Chen, Z., and E.J. Wherry. 2020. T cell responses in patients with COVID-19. *Nat Rev Immunol*
456 20:529-536.
- 457 Cox, R.J., and K.A. Brokstad. 2020. Not just antibodies: B cells and T cells mediate immunity to
458 COVID-19. *Nat Rev Immunol* 20:581-582.
- 459 Favresse, J., C. Eucher, M. Elsen, M. Tre-Hardy, J.M. Dogne, and J. Douxfils. 2020. Clinical
460 performance of the Elecsys electrochemiluminescent immunoassay for the detection of
461 SARS-CoV-2 total antibodies. *Clin Chem* 66:1104-1106.
- 462 Grifoni, A., D. Weiskopf, S.I. Ramirez, J. Mateus, J.M. Dan, C.R. Moderbacher, S.A. Rawlings,
463 A. Sutherland, L. Premkumar, R.S. Jadi, D. Marrama, A.M. de Silva, A. Frazier, A.F.
464 Carlin, J.A. Greenbaum, B. Peters, F. Krammer, D.M. Smith, S. Crotty, and A. Sette.
465 2020. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-
466 19 disease and unexposed individuals. *Cell* 181:1489-1501 e1415.
- 467 Hanekom, W.A., J. Hughes, M. Mavinkurve, M. Mendillo, M. Watkins, H. Gamielien, S.J.
468 Gelderbloem, M. Sidibana, N. Mansoor, V. Davids, R.A. Murray, A. Hawkrige, P.A.
469 Haslett, S. Ress, G.D. Hussey, and G. Kaplan. 2004. Novel application of a whole blood
470 intracellular cytokine detection assay to quantitate specific T-cell frequency in field
471 studies. *J Immunol Methods* 291:185-195.
- 472 Jubel, J.M., Z.R. Barbati, C. Burger, D.C. Wirtz, and F.A. Schildberg. 2020. The role of PD-1 in
473 acute and chronic infection. *Front Immunol* 11:487.
- 474 Juno, J.A., D. van Bockel, S.J. Kent, A.D. Kelleher, J.J. Zaunders, and C.M. Munier. 2017.
475 Cytotoxic CD4 T cells - Friend or foe during viral infection? *Front Immunol* 8:19.
- 476 Le Bert, N., A.T. Tan, K. Kunasegaran, C.Y.L. Tham, M. Hafezi, A. Chia, M.H.Y. Chng, M. Lin,
477 N. Tan, M. Linster, W.N. Chia, M.I. Chen, L.F. Wang, E.E. Ooi, S. Kalimuddin, P.A.
478 Tambyah, J.G. Low, Y.J. Tan, and A. Bertoletti. 2020. SARS-CoV-2-specific T cell
479 immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* 584:457-
480 462.

- 481 Lipsitch, M., Y.H. Grad, A. Sette, and S. Crotty. 2020. Cross-reactive memory T cells and herd
482 immunity to SARS-CoV-2. *Nat Rev Immunol* 20:709-713.
- 483 Liu, L., W. Liu, Y. Zheng, X. Jiang, G. Kou, J. Ding, Q. Wang, Q. Huang, Y. Ding, W. Ni, W.
484 Wu, S. Tang, L. Tan, Z. Hu, W. Xu, Y. Zhang, B. Zhang, Z. Tang, X. Zhang, H. Li, Z.
485 Rao, H. Jiang, X. Ren, S. Wang, and S. Zheng. 2020a. A preliminary study on serological
486 assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238
487 admitted hospital patients. *Microbes Infect* 22:206-211.
- 488 Liu, Y., L.M. Yan, L. Wan, T.X. Xiang, A. Le, J.M. Liu, M. Peiris, L.L.M. Poon, and W. Zhang.
489 2020b. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* 20:656-
490 657.
- 491 Margolin, E., W.A. Burgers, E.D. Sturrock, M. Mendelson, R. Chapman, N. Douglass, A.L.
492 Williamson, and E.P. Rybicki. 2020. Prospects for SARS-CoV-2 diagnostics, therapeutics
493 and vaccines in Africa. *Nat Rev Microbiol* DOI: 10.1038/s41579-020-00441-3:
- 494 Mathew, D., J.R. Giles, A.E. Baxter, D.A. Oldridge, A.R. Greenplate, J.E. Wu, C. Alanio, L.
495 Kuri-Cervantes, M.B. Pampena, K. D'Andrea, S. Manne, Z. Chen, Y.J. Huang, J.P. Reilly,
496 A.R. Weisman, C.A.G. Ittner, O. Kuthuru, J. Dougherty, K. Nzingha, N. Han, J. Kim, A.
497 Pattekar, E.C. Goodwin, E.M. Anderson, M.E. Weirick, S. Gouma, C.P. Arevalo, M.J.
498 Bolton, F. Chen, S.F. Lacey, H. Ramage, S. Cherry, S.E. Hensley, S.A. Apostolidis, A.C.
499 Huang, L.A. Vella, U.P.C.P. Unit, M.R. Betts, N.J. Meyer, and E.J. Wherry. 2020. Deep
500 immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic
501 implications. *Science* 369. DOI: 10.1126/science.abc8511:
- 502 Mendelson, M., L. Boloko, A. Boutall, L. Cairncross, G. Calligaro, C. Coccia, J.A. Dave, M. de
503 Villiers, S. Dlamini, P. Frankenfeld, P. Gina, M.V. Gule, J. Hoare, R. Hofmeyr, M. Hsiao,
504 I. Joubert, T. Kahn, R. Krause, A. Kroopman, D. Levin, D. Maughan, S. Mazondwa, G.
505 Meintjes, R. Nordien, N. Ntusi, N. Papavarnavas, J. Peter, H. Pickard, P. Raubenheimer,
506 Q. Said-Hartley, P. Singh, S. Wasserman, and o.b.o.t.G.S.H.C.-R. Team. 2020. Clinical
507 management of COVID-19: Experiences of the COVID-19 epidemic from Groote Schuur
508 Hospital, Cape Town, South Africa. *South African Medical Journal* 110:973-981.
- 509 Mou, H., B.D. Quinlan, H. Peng, Y. Guo, S. Peng, L. Zhang, M.E. Davis-Gardner, M.R. Gardner,
510 G. Crynen, Z.X. Voo, C.C. Bailey, M.D. Alpert, C. Rader, H. Choe, and M. Farzan. 2020.
511 Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-
512 CoV-2. *BioRxiv* DOI: 10.1101/2020.06.29.178459:
- 513 Muench, P., S. Jochum, V. Wenderoth, B. Ofenloch-Haehnle, M. Hombach, M. Strobl, H.
514 Sadlowski, C. Sachse, G. Torriani, I. Eckerle, and A. Riedel. 2020. Development and
515 validation of the Elecsys anti-SARS-CoV-2 immunoassay as a highly specific tool for
516 determining past exposure to SARS-CoV-2. *J Clin Microbiol* 58. DOI:
517 10.1128/JCM.01694-20:
- 518 National, S.-C.-S.A.E.G. 2020. Performance characteristics of five immunoassays for SARS-
519 CoV-2: a head-to-head benchmark comparison. *Lancet Infect Dis*. DOI: 10.1016/S1473-
520 3099(20)30634-4:
- 521 Ogbe, A., B. Kronsteiner, D.T. Donal T. Skelly, M. Pace, and A. Brown. 2020. T cell assays
522 differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral
523 responses. *MedRxiv* DOI: 10.1101/2020.1109.1128.20202929.
- 524 Pachnio, A., M. Ciaurriz, J. Begum, N. Lal, J. Zuo, A. Beggs, and P. Moss. 2016.
525 Cytomegalovirus infection leads to development of high frequencies of cytotoxic virus-
526 specific CD4+ T cells targeted to vascular endothelium. *PLoS Pathog* 12:e1005832.
- 527 Quinti, I., V. Lougaris, C. Milito, F. Cinetto, A. Pecoraro, I. Mezzaroma, C.M. Mastroianni, O.
528 Turriziani, M.P. Bondioni, M. Filippini, A. Soresina, G. Spadaro, C. Agostini, R. Carsetti,
529 and A. Plebani. 2020. A possible role for B cells in COVID-19? Lesson from patients
530 with agammaglobulinemia. *J Allergy Clin Immunol* 146:211-213 e214.
- 531 Riou, C., E. Du Bruyn, S. Ruzive, R.T. Goliath, C.S. Lindestam Arlehamn, A. Sette, A. Sher,
532 D.L. Barber, and R.J. Wilkinson. 2020. Disease extent and anti-tubercular treatment

- 533 response correlates with *Mycobacterium tuberculosis*-specific CD4 T-cell phenotype
534 regardless of HIV-1 status. *Clin Transl Immunology* 9:e1176.
- 535 Rogers, T.F., F. Zhao, D. Huang, N. Beutler, A. Burns, W.T. He, O. Limbo, C. Smith, G. Song, J.
536 Woehl, L. Yang, R.K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S.
537 Ramirez, J. Ricketts, M.J. Ricciardi, S.A. Rawlings, N.C. Wu, M. Yuan, D.M. Smith, D.
538 Nemazee, J.R. Teijaro, J.E. Voss, I.A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok,
539 J.G. Jardine, and D.R. Burton. 2020. Isolation of potent SARS-CoV-2 neutralizing
540 antibodies and protection from disease in a small animal model. *Science* 369:956-963.
- 541 Rydyznski Moderbacher, C., S.I. Ramirez, J.M. Dan, A. Grifoni, K.M. Hastie, D. Weiskopf, S.
542 Belanger, R.K. Abbott, C. Kim, J. Choi, Y. Kato, E.G. Crotty, C. Kim, S.A. Rawlings, J.
543 Mateus, L.P.V. Tse, A. Frazier, R. Baric, B. Peters, J. Greenbaum, E. Ollmann Saphire,
544 D.M. Smith, A. Sette, and S. Crotty. 2020. Antigen-specific adaptive immunity to SARS-
545 CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell*. DOI:
546 10.1016/j.cell.2020.09.038:
- 547 Sattler, A., S. Angermair, H. Stockmann, K.M. Heim, D. Khadzhynov, S. Treskatsch, F. Halleck,
548 M.E. Kreis, and K. Kotsch. 2020. SARS-CoV-2 specific T-cell responses and correlations
549 with COVID-19 patient predisposition. *J Clin Invest*. DOI: 10.1172/JCI140965:
- 550 Schub, D., V. Klemis, S. Schneitler, J. Mihm, P.M. Lepper, H. Wilkens, R. Bals, H. Eichler, B.C.
551 Gartner, S.L. Becker, U. Sester, M. Sester, and T. Schmidt. 2020. High levels of SARS-
552 CoV-2-specific T cells with restricted functionality in severe courses of COVID-19. *JCI*
553 *Insight* 5:e142167.
- 554 Sekine, T., A. Perez-Potti, O. Rivera-Ballesteros, K. Stralin, J.B. Gorin, A. Olsson, S. Llewellyn-
555 Lacey, H. Kamal, G. Bogdanovic, S. Muschiol, D.J. Wullimann, T. Kammann, J. Emgard,
556 T. Parrot, E. Folkesson, C.-S.G. Karolinska, O. Rooyackers, L.I. Eriksson, J.I. Henter, A.
557 Sonnerborg, T. Allander, J. Albert, M. Nielsen, J. Klingstrom, S. Gredmark-Russ, N.K.
558 Bjorkstrom, J.K. Sandberg, D.A. Price, H.G. Ljunggren, S. Aleman, and M. Buggert.
559 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild
560 COVID-19. *Cell* 183:158-168 e114.
- 561 Sester, U., D. Presser, J. Dirks, B.C. Gartner, H. Kohler, and M. Sester. 2008. PD-1 expression
562 and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible
563 functional anergy. *Am J Transplant* 8:1486-1497.
- 564 Sette, A., and S. Crotty. 2020. Pre-existing immunity to SARS-CoV-2: the knowns and
565 unknowns. *Nat Rev Immunol* 20:457-458.
- 566 Wherry, E.J., and M. Kurachi. 2015. Molecular and cellular insights into T cell exhaustion. *Nat*
567 *Rev Immunol* 15:486-499.
- 568 Wykes, M.N., and S.R. Lewin. 2018. Immune checkpoint blockade in infectious diseases. *Nat*
569 *Rev Immunol* 18:91-104.
- 570 Zheng, H.Y., M. Zhang, C.X. Yang, N. Zhang, X.C. Wang, X.P. Yang, X.Q. Dong, and Y.T.
571 Zheng. 2020. Elevated exhaustion levels and reduced functional diversity of T cells in
572 peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol*
573 *Immunol* 17:541-543.
- 574

	Healthcare Workers (n=31)			
n	15	7	9	<i>P</i> -value
Self-reported symptoms	No	Yes	Yes	-
Tested for COVID	No	Yes	Yes	-
Positive SARS-CoV-2 PCR	na	No	Yes	-
Positive SARS-CoV-2 N-spe IgG (%) ^a	0%	0%	88.9% (8/9)	-
Presence of SARS nAbs (%) ^b	0%	0%	100%	-
Contact with COVID patients (%)	86.6%	100%	88.9%	ns
Time post PCR test (weeks) ^c	na	7.3 [6.3-8.4]	4.7 [2.6-7.2]	0.09

Table 1: Clinical characteristics of study participants

^a Measured using the Elecsys® Roche system

^b Measured using a SARS-CoV-2 pseudovirus neutralisation assay

^c Median and Interquartile range (IQR)

Figure 1





Figure 2







Figure 4










Figure 6




Markers	Fluorochrome	Clone	Company	Cat. Number	Role
CD3	BV650	OKT3	BioLegend	317323	Lineage
CD4	BV785	OKT4	BioLegend	317428	
CD8	BV510	RPA-T8	BioLegend	301048	
CD45RA	Alexa 488	HI100	BioLegend	304114	Memory differentiation
CD27	PE-Cy5	1A4CD27	Beckman	6607107	
CD38	APC	HIT2	BD Bioscience	555462	Activation
HLA-DR	BV605	L243	BioLegend	307640	
Ki67	PerCP-Cy5.5	B56	BD Bioscience	561284	
PD-1	PE	EH12.2H7	BioLegend	329906	
GrB	BV421	GB11	BD Bioscience	563388	Cytotoxic potential
IFNγ	BV711	4S.B3	BioLegend	502540	Functions
TNFα	PE-Cy7	MAB11	BioLegend	502930	
IL-2	PE/Dazzle™ 594	MQ1-17H12	BioLegend	500344	

Supp table 1: Description of the antibody panel used in the study.



Supp Figure 1: Gating strategy used to identify SARS-CoV-2 specific CD4 T cells and defined their phenotypic characteristics. **A-** Cell lineage. **B-** Phenotyping of total CD4 T cell and cytokine production in response to SARS-CoV-2 peptides. **C-** Phenotype of SARS-CoV-2 responding CD4 T cells in one participant with no symptom (left) and one COVID-19 confirmed participant (right). SARS-CoV-2-specific CD4 T cells (expressing any measured cytokine) are depicted in red.



Supp Figure 2: Comparison of magnitude of SARS-CoV-2-specific CD4 T cell response expressing TNF α , IL-2 or IFN γ in participants exhibiting a detectable response to SARS-CoV-2 peptide pool. Each dot represent a participant and is color-coded according to clinical characteristics (Blue represents no symptoms, no SARS-CoV-2 PCR performed; Orange: self-reported symptoms, SARS-CoV-2 PCR negative and Red: self-reported symptoms, SARS-CoV-2 PCR positive). Black bars indicate medians. Statistical comparisons were performed using a nonparametric paired Friedman test.